Jacobs Levy Equity Management
BIOR

Jacobs Levy Equity Management’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-368
Closed -$438K – 1147
2021
Q1 		$438K Sell
368
-162
-31% -$223K ﹤0.01% 877
2020
Q4 		$704K Buy
530
+422
+391% +$619K 0.01% 801
2020
Q3 		$243K Buy
+108
New +$244K ﹤0.01% 925

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's BIOR Position: Q2 2021 in Review

Jacobs Levy Equity Management sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2021, closing a stake of 368 shares — an estimated $438K sold.

Jacobs Levy Equity Management first reported a position in BIOR in Q3 2020 and held it in 3 quarters. The position peaked at $704K in Q4 2020. 42 funds tracked by Wall St. Rank hold BIOR as of Q2 2021.

  • Jacobs Levy Equity Management reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 368 Biora Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $438K.
  • Jacobs Levy Equity Management first reported a position in Biora Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Biora Therapeutics, Inc. Common Stock position peaked at $704K in Q4 2020.
  • 42 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.